When was Assertio founded?

Assertio was founded in 1995 and raised its 1st funding round 3 years after it was founded.

Where is Assertio located?

Assertio is headquartered in Lake Forest, United States.

How many employees does Assertio have?

As of Apr 30, 2026, the latest employee count at Assertio is 64.

Is Assertio a funded company?

Assertio is a funded company, having raised an undisclosed amount across 5 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Feb 24, 1998.

When was the latest funding round of Assertio?

Assertio's latest funding was a $***** Conventional Debt round on Mar 12, 2015, with participation from 1 investor.

What is the annual revenue of Assertio?

Annual revenue of Assertio is $230M as on Dec 31, 2019.

Where does Assertio rank among its competitors?

Assertio ranks 315th amongst 2716 active competitors, of which 915 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was C4 Therapeutics, which secured $25M in Jan, 2024.

Who are the top competitors of Assertio?

Assertio's top competitors include Jazz Pharmaceuticals, argenx and Sana Biotechnology. Among them, C4 Therapeutics secured the most recent funding round in January, 2024.

Assertio - 2026 Company Profile, Team, Funding, Competitors & Financials

Q: Is Assertio an acquired company?

Assertio got acquired by Garda Therapeutics on Apr 08, 2026.

Company Details

Developer of drugs to treat pain and other neurological diseases. It offers Nucynta ER indicated for the management of pain associated with diabetic peripheral neuropathy (DPN), Gralise for the management of postherpetic neuralgia (PHN), Cambia for acute treatment of migraine attacks, Lazanda for the management of breakthrough pain in cancer patients; and Zipsor, liquid filled capsules for relief of mild to moderate acute pain. Its pipeline developing drugs include cebranopadol, analgesic for the treatment of moderate to severe chronic nociceptive and neuropathic pain.

Website: www.assertiotx.com
Email ID: *****@assertiotx.com, *****@assertiotx.com
Phone Number: +1 **********

Key Metrics

Founded Year

1995

Location

Lake Forest, United States

Stage

Acquired

Latest Funding Round

Conventional Debt, Mar 12, 2015, $*****

Investors

Deerfield & 10 more

Ranked

315^th among 2716 active competitors

Annual Revenue

$230M as on Dec 31, 2019

Employee Count

64 as on Apr 30, 2026

Investment & Acquisitions

Spectrum Pharmaceuticals & 1 more

Similar Companies

Heron Therapeutics & 299 more

Exit Details

Acquired by Garda Therapeutics (Apr 08, 2026)

View Assertio's full profile

Assertio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ASSERTIO THERAPEUTICS, INC CIN: 1005201 , United States, Active	Jul 17, 2018	$230M (As on Dec 31, 2019)	-	-

Assertio got acquired by Garda Therapeutics on Apr 08, 2026 at an acquisition amount of $*****.

Click here to take a look at Assertio's acquisition in detail

Assertio has raised funding over 5 rounds. Its first funding round was on Feb 24, 1998. Its latest funding round was a Conventional Debt round on Mar 12, 2015 for $*****. 1 investor participated in its latest round. Assertio has 11 institutional investors.

Here is the list of recent funding rounds of Assertio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 12, 2015	2554673	Conventional Debt	1087925	3358544	6935076	5988221
Sep 04, 2014	6446627	Post IPO	1401933	1225169	9526625	4195380
Jun 30, 2008	6302102	Conventional Debt	8249665	9085986	1836879	Oxford Finance & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Assertio's funding rounds and investors

The founders of Assertio is John Shell.

Here are the details of Assertio's key team members:

John Shell: Founder of Assertio.
Arthur Higgins: CEO of Assertio. They serve on the board of 1 company.

View details of Assertio's Founder profiles and Board Members

Assertio's employee count trend

Assertio has 64 employees as of Apr 26. Here is Assertio's employee count trend over the years:

Uncover Assertio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Assertio include Jazz Pharmaceuticals, argenx and Sana Biotechnology. Here is the list of Top 10 competitors of Assertio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Omnes Capital & 20 others	76/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
9th	Harbour BioMed 2016, Shanghai (China), Public	Developer of antibody therapeutics in immunology and oncology disease	$313M	Hudson Bay Capital, GIC & 19 others	71/100
10th	iTeos Therapeutics 2011, Cambridge (United States), Acquired	Developer of immunotherapy for treating cancer	$204M	Boxer Capital, RA Capital Management & 19 others	70/100
315th	Assertio 1995, Lake Forest (United States), Acquired	Developer of drugs to treat pain and other neurological diseases	-	Deerfield, GE Healthcare Equipment Finance ... & 9 others	52/100